CTCs
OneCell Diagnostics Raises $16M in Series A Round
The precision oncology company plans to bring its OncoIndx Ikon liquid biopsy circulating tumor cell detection test to the US market.
USC Team Counts Circulating Tumor Cells to Predict Treatment Response, Survival in Prostate Cancer
Premium
The researchers used the CellSearch assay to measure circulating tumor cells and determine the response to certain treatments as well as survival outcomes.
Angle Acquires Option to License NuProbe Pan-Cancer NGS Panel
Angle said the panel would help advance its efforts to develop a liquid biopsy assay for circulating tumor cells and ctDNA.
Angle Raises $630K in Open Offer of Shares
The company said the proceeds will strengthen its balance sheet as it works to advance its circulating tumor cell platform for diagnostics and drug development.
Angle to Develop Prostate Cancer Liquid Biopsy Assay for AstraZeneca
The company will use its Parsortix platform to develop a circulating tumor cell-based assay to measure androgen receptor status in therapy response.
Oct 31, 2022
Aug 18, 2021
Mar 31, 2021